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ABSTRACT
Introduction: The overall mortality rate for cancer has
declined in Australia. However, socioeconomic
inequalities exist and the out-of-pocket costs incurred
by patients in Australia are high compared with some
European countries. There is currently no readily
available data set to provide a systematic means of
measuring the out-of-pocket costs incurred by patients
with cancer within Australia. The primary aim of the
project is to quantify the direct out-of-pocket
healthcare expenditure of individuals in the state of
Queensland, who are diagnosed with cancer.
Methods and analysis: This project will build
Australia’s first model (called CancerCostMod) of out-
of-pocket healthcare expenditure of patients with
cancer using administrative data from Queensland
Cancer Registry, for all individuals diagnosed with any
cancer in Queensland between 1 July 2011 and 30
June 2012, linked to their Admitted Patient Data
Collection, Emergency Department Information System,
Medicare Benefits Schedule and Pharmaceutical
Benefits Scheme records from 1 July 2011 to 30 June
2015. No identifiable information will be provided to
the authors. The project will use a combination of
linear and logistic regression modelling, Cox
proportional hazards modelling and machine learning
to identify differences in survival, total health system
expenditure, total out-of-pocket expenditure and high
out-of-pocket cost patients, adjusting for demographic
and clinical confounders, and income group,
Indigenous status and geographic location. Results will
be analysed separately for different types of cancer.
Ethics and dissemination: Human Research Ethics
approval has been obtained from the Townsville
Hospital and Health Service Human Research Ethics
Committee (HREC/16/QTHS/110) and James Cook
University Human Research Ethics Committee (H6678).
Permission to waive consent has been sought from
Queensland Health under the Public Health Act 2005.
INTRODUCTION
In Australia, the overall mortality rate for
cancer declined by 20% between 1982 and
2014.1 Among Australians, however, differ-
ences still remain in the likelihood of survival
depending on socioeconomic status: 13% of
cancer deaths were attributable to socio-
economic inequalities.2 Differences in inci-
dence and survival are also reported in
Australia according to geographical loca-
tion,3–7 and Indigenous status.3 8–10 In
Australia, these population groups commonly
overlap, with a greater proportion of
Indigenous Australians residing in remote
and very remote areas,11 and a greater pro-
portion of Australians living in rural and
remote areas experience disadvantage with
respect to education, employment, and
access to goods and services.12
Part of understanding these discrepancies
may involve quantifying out-of-pocket health-
care costs. Within Australia, 21% of patients
with cancer have stated they miss care due to
the cost.13 If a treatment imposes significant
financial strain on families then this may
affect their decisions to access care. Being
able to quantify the out-of-pocket costs faced
by patients with cancer is a vital yet currently
missing component of understanding the
impact of cancer on patients’ lives, socio-
economic disparities in clinical outcomes,
and the patients’ journey through the health-
care system. Currently, there is no systematic
and robust means of measuring total
out-of-pocket medical expenses of patients
with cancer that does not rely on self-reported
data. This project seeks to fill this gap.
Australia has a universal healthcare system,
Medicare, which provides the population with
access to essential healthcare services at no
charge to the end user or for a subsidised
fee.14 Additional private health insurance is
Strengths and limitations of this study
▪ Census of Queensland Cancer Registry.
▪ Linkage of administrative data.
▪ Data obtained for one state of Australia.
▪ No inclusion of indirect costs.
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optional. Access to care in public hospitals is generally
free of charge; however, any care provided in private hos-
pitals is not covered by Medicare and must be paid by the
patient or private health insurance. For care outside of a
hospital, some services are ‘bulk billed’, meaning that the
full cost of treatment is billed directly to Medicare and
the patients do not face any up-front or out-of-pocket
charges. However, many services do have an
‘out-of-pocket’ charge that is paid for by the patient, this
occurs when the fee charged by the service provider is
higher than the rebate paid by Medicare. These provider
fees for out of hospital care are not regulated, and provi-
ders are able to set their own fees. This has led to occur-
rences where some providers may charge more for certain
patients based on their perceived ability to afford care.15
It is well established that cancer in particular is a
costly chronic health condition. The Costs of Cancer in
New South Wales (NSW) report identified a total of $3.9
billion in total expected lifetime financial costs (which
includes health system and productivity costs) for people
diagnosed with cancer in NSW in 2005. The report iden-
tified that the individual bears 40% of these costs.16
While this does highlight the extent of the costs faced by
patients, the methods used in this report are based on
aggregated data rather than individual data. Aggregated
data does not allow for estimates to be stratified by
patient characteristics, the identification of groups who
face disproportionately high costs, or allow for different
changes to health funding to be modelled. This is a
major weakness as it is recognised that there are large
variations in out-of-pocket expenditure between differ-
ent patients with cancer,17 for example between those in
rural areas compared with those in major cities.18 Using
individual level data, as is proposed in this research
project, would overcome these weaknesses.
Other studies within Australia of the out-of-pocket
costs faced by patients with cancer and their families
have the drawback of focusing on small subpopulations,
such as those from a specific geographic area or age
group.18–20 Such studies are unable to produce general-
isable results and are also based on self-reported data.21
One study has looked at the ability of telehealth to
reduce travel costs,22 which are a significant component
of out-of-pocket costs for patients;20 however, this study
was only conducted for one small area of Australia. Most
cost-effectiveness studies undertaken as a part of clinical
trials, both within Australia and internationally, do not
take a patient perspective or make specific note of the
level of out-of-pocket costs faced by patients23–26 and
whether this amount would be affordable and sustain-
able. The Cancer 2015 project27 is linking hospital data
with Medicare claims records for patients with cancer in
Victoria, Australia. However, it is based on recruited
patients and is thus subject to recruitment bias, and it is
not supplemented with patient’s perspectives of treat-
ment and reports of foregone care.
We propose to create a model of health service use and
cost called CancerCostMOD, which will include most
direct out-of-pocket costs associated with treatment: pro-
vider charges for out of hospital services covered by the
Medicare Benefits Schedule, pharmaceutical costs for pre-
scription medications covered by the Pharmaceutical
Benefits Scheme and over the counter medications, and
travel time. The model will fill the gap in health economic
practice within the cancer field regarding out-of-pocket
costs. It will allow the accurate estimation of current direct
out-of-pocket costs faced by patients with cancer in
Queensland, Australia by using administrative data.
The aims of this study are:
1. To determine any inequalities (based on income
group, Indigenous status and geographic location) in
cancer incidence in Queensland, Australia;
2. To quantify any inequalities (based on income group,
Indigenous status and geographic location) in health
system use and expenditure on cancer in
Queensland, Australia, including hospital admitted
patient services, out-of-hospital services and prescrip-
tion pharmaceuticals;
3. To quantify the out-of-pocket healthcare expenditure of
individuals in Queensland, Australia who are diagnosed
with cancer, and any inequalities (based on income
group, Indigenous status and geographic location);
4. To quantify the travel savings associated with tele-
health oncology services in Queensland, Australia,
and any inequalities (based on income group,
Indigenous status and geographic location).
While the overall focus of this study is patient’s
out-of-pocket expenditure, aims 1 and 2 will provide a
baseline description in socioeconomic inequalities in
cancer incidence and general health service use.
METHODS
Study setting
For its base population, CancerCostMOD will use a
census of patients diagnosed with cancer between 1 July
2011 and 30 June 2012, from the Queensland Cancer
Registry and thus will not be subject to recruitment bias.
It will therefore be able to capture the direct healthcare
expenditure of all people diagnosed with cancer in
Queensland. Queensland has a relatively large propor-
tion of its population living outside major cities, and a
relatively large proportion of its population identifying
as Aboriginal and/or Torres Strait Islander.28 Such
populations have a relatively high risk of developing
cancer and are often diagnosed at a late stage,29 but can
also be under-represented in national surveys.30 They
also face additional costs in accessing treatment for
cancer—direct transport costs, and indirect costs such as
loss of income and caring costs due to prolonged time
away from home.20 As such, Queensland-based data pro-
vides an opportunity to capture results from the at-risk
and under-represented populations.
Data
Data from the Queensland Cancer Registry will be pro-
vided to Queensland Health, who will then link this data
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with the Queensland Health Admitted Patient Data
Collection (QHAPDC) and the Emergency Department
Information System (EDIS). The QHAPDC data set
records every hospitalisation in Queensland’s public and
private hospitals and contains variables on comorbidity,
private health insurance, hospital type where admitted,
and patient type of admission (public or private). The
EDIS contains records of each presentation at emer-
gency departments across Queensland. For each of the
individuals extracted from the Queensland Cancer
Registry, all of their data from the QHAPDC and EDIS
will be requested from 01 July 2011 to 30 June 2015,
accounting for multiple admissions and presentations.
The combined Queensland Cancer Registry, QHAPDC
and EDIS data set will subsequently be linked by the
Australian Institute of Health and Welfare (AIHW) with
Medicare Benefits Schedule (MBS) and Pharmaceutical
Benefits Scheme (PBS) records for 2011, 2012, 2013,
2014 and 2015 using full name, date of birth and
address for matching individuals. AIHW will remove all
identifying characteristics and return the complete data
set to the research group at James Cook University.
The resultant de-identified data set will then be
returned to the research group, and contain demographic
variables, diagnosis, clinical outcome measures, plus
healthcare use and out-of-pocket expenditure as follows.
Queensland Cancer Registry
The information obtained from the Queensland Cancer
Registry will contain patient demographics at diagnosis
and information regarding type of cancer, including
stage and grade.
MBS and PBS services
The MBS and PBS claims records contains the MBS
item number, PBS item code, and the patient contribu-
tion rate paid for each service accessed by the patient.
Hospital use
The QHAPDC identifies whether a patient was admitted at
a private or public hospital, and whether they were admit-
ted as a private or public patient. For individuals who were
admitted as an uninsured patient at a private hospital, the
cost attributed to their admission will be calculated from
the total Australian Refined Diagnostic-Related Group
(AR-DRG) cost weights, less any Medicare rebate. The
MBS and PBS data contain a flag for whether any costs
were incurred during a hospitalisation, which allows the
out-of-pocket costs for private patients admitted at private
hospitals to also be identified.
The EDIS identifies the triage category assigned to
each presentation. The National Efficient Price appor-
tioned to each triage category by the Independent
Hospital Pricing Authority will be used to allocate a cost
to each presentation to an emergency department.
The research team will then estimate a number of
items as follows:
MBS items with a capped number of services: the records
of patients who have received the maximum number of
allowable services will be identified. Using the 2011–
2012 Australian Health Survey, the average annual
number of these services reported by respondents with
malignant neoplasms and similar demographic
characteristics will be used to estimate the total number
of services accessed each year. Out-of-pocket cost per
item will be based on the MBS schedule price.
Over the counter medication use: will also be estimated
using the 2011–2012 Australian Health Survey from indi-
viduals with similar demographic characteristics.
Out-of-pocket expenditure amounts paid for over the
counter medication will be obtained from the price
listed on Arrow Private Prescription Program.
Travel costs: will be estimated based on MBS and PBS
data, which lists postcode of residence and postcode of
service use, and the Australian Tax Office cents per kilo-
metre formula will be applied to estimate car expenses.
From this point the full range of health system related
out-of-pocket healthcare costs will be captured by
CancerCostMOD, with data sources for use and cost
detailed below in table 1.
All health services use, regardless of whether it is dir-
ectly attributable to cancer or not, will be included.
This avoids the difficulty in identifying underlying
the clinical reason for health service use, and also the
risk of overlooking unexpected clinical consequences
of cancer.31 32
Analysis
All analysis will be stratified by cancer type, with a focus
on the cancers with the highest incidence, to allow for
sufficient sample numbers.
Table 1 Data sources for health service use and cost
Resource item
Data source for
number of
services
Data source for
cost per service
use
PBS
prescriptions
Medicare claim
records
Medicare claim
records
MBS items Medicare claim
records
Medicare claim
records
MBS items with
capped services
Australian Health
Survey
Medicare claim
records
Hospital services QHAPDC
EDIS
AR-DRG codes,
Medicare claim
records
IHPA National
Efficient Price
Over the counter
medication
Australian Health
Survey
Arrow Prescription
Program
Travel—car
expenses
Medicare claim
records
Australian Tax
Office formula
AR-DRG, Australian Refined Diagnostic-Related Group; EDIS,
Emergency Department Information System; IHPA, Independent
Hospital Pricing Authority; MBS, Medicare Benefits Schedule;
PBS, Pharmaceutical Benefits Scheme; QHAPDC, Queensland
Health Admitted Patient Data Collection.
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Aim 1
The Queensland Cancer Registry and the 2011
Australian Bureau of Statistics (ABS) National
Population Census will be used to calculate the inci-
dence rate of cancer in Queensland. This has previously
been done in Queensland;4 7 however, this project will
provide more recent statistics as well as a stratified ana-
lysis to identify inequalities by income group,
Indigenous status and geography.
Aim 2
The average health system use (including average
annual number of general practitioner consultations,
specialist consultations, and hospital admissions) and
the associated health system costs per patient will then
be quantified for Indigenous and non-Indigenous
patientsi, income group (those with and without low-
income healthcare cardsii), and people living in differ-
ent geographic areas across Queenslandiii to identify
inequalities. The total cost of care for each patient will
be divided into quintiles and then further divided into
the two highest cost groups.
Decision tree learning will be used to determine if
there are any possibly explanatory variables which
predict a ‘high-cost patient’. This method is a type of
predictive modelling machine learning, which enables
the user to input multiple variables into the analysis soft-
ware, such as SAS to produce a decision tree (crude
example shown in figure 1). The program identifies the
combination of variables that are the biggest predictors
of the variable of interest, and splits the data into
branch-like segments depending on the rule(s) applied.
The hierarchy of the decision tree starts at the root
node (top), and splits into the various nodes
(branches).33
A crude example of what a decision tree might look
like is below (figure 1), which shows the probability of a
person being a ‘high-cost patient’. The values in this
figure are purely as an example, where 1=high-cost
patient, and 0=low-cost patient. The first variable (ie,
gender) shows a fairly even distribution of men and
women being ‘high-cost patients’; however, the second
variable (x) shows a difference in the proportion.
Logistic regression will be used to determine the OR of
being a ‘high-cost’ patient. The explanatory variables will
be income group, Indigenous status, geographic location,
age, sex and any other variables identified in the
machine learning phase to be predictive of high cost.
Aim 3
The differences in patient out-of-pocket healthcare
expenditure across different socioeconomic groups will
be modelled using linear regression modelling, with a
particular focus on difference in out-of-pocket expend-
iture between Indigenous and non-Indigenous patients,
income group, and people living in different geographic
areas across Queensland. The outcomes (death and
readmission within 30 days) of patients with similar
initial clinical characteristics will also be compared for
those identified as high or low out-of-pocket expend-
iture patients, using Cox proportional hazards, and logis-
tic regression models, adjusting for income group,
Indigenous status, geographic location, age and sex.
This analysis will be conducted using SAS V.9.4.
Geographic analysis will be conducted using SAS V.9.4
and ArcGIS by Primary Health Network (PHN) and
Health Service District. The average out-of-pocket cost
per patient, adjusted for income group, Indigenous
status, geographic location, age and sex, will be identi-
fied for each PHN across Queensland.
Aim 4
The travel cost savings of the telehealth services in
Queensland will be determined by analysing the travel
costs associated with patients who received any tele-
health compared with the travel costs to the patient if
this service was not available.
On the basis of the methods published by Thaker
et al,18 2013, we will seek to replicate the study across
Queensland to analyse the savings conferred by
Figure 1 Crude example of decision tree for high-cost patients. This figure shows a crude example of a decision tree, produced
by using predictive modelling machine learning. The program identifies the combination of variables that are the biggest
predictors of the variable of interest.
iIdentified from Queensland Cancer Registry.
iiIdentified from PBS claims records.
iiiIdentified from postcodes on Queensland Cancer Registry mapped to
Australia/Remoteness Index of Australia.
4 Callander E, et al. BMJ Open 2017;7:e014030. doi:10.1136/bmjopen-2016-014030
Open Access
telehealth service compared with the counterfactual
scenario where teleoncology had not been available.
The outcome of interest is travel cost-savings (continu-
ous numerical variable), a generalised linear model will
be used to identify differences in savings associated with
teleoncology associated with subpopulation groups
(Indigenous and non-Indigenous patients, income
group, and people living in different geographic areas
across Queensland) adjusting for age and sex.
LIMITATIONS
While the use of administrative data provides many ben-
efits for analysis, it is acknowledged that certain, mostly
indirect costs, will not be captured. This includes costs
of productivity loss and carer time. Out of hospital ser-
vices not covered by the Medicare Benefits Schedule,
such as MRIs, will also not be captured.
DISSEMINATION
Consent will not be sought from participants whose
de-identified data will be used in this study. Permission
to waive consent has been sought from Queensland
Health under the Public Health Act 2005. No identifi-
able information will be provided to the authors.
A series of reports for each PHN and Hospital and
Health Service in Queensland will be developed, outlin-
ing the out-of-pocket healthcare expenditure of patients
with cancer within their jurisdiction, the impact this has
on access care, and relationship with patient outcomes.
The project will highlight the potential for the medical
profession to directly impact on the living standards of
their patients—beyond their health status—by routinely
measuring the health system costs of their research, and
the out-of-pocket costs to the patient. By presenting the
results across each PHN and Health and Hospital
Service in Queensland, health professionals working
within different jurisdictions will be able to compare
how much their patients are paying relative to others.
CONCLUSIONS
Given the current heightened level of community discus-
sion within Australia about increases to out-of-pocket
healthcare costs, it is imperative to know the current,
actual out-of-pocket healthcare costs, particularly for
patients with cancer for whom it is recognised that
out-of-pocket expenditure may be particularly high.16
The recent Senate Inquiry into out-of-pocket healthcare
expenditure within Australia recommended ‘a compre-
hensive review of the impact of existing co-payments on
individuals’ access to health services’,34 which this timely
and much-needed project will go some way towards
addressing. This information would allow governments
and healthcare providers within Australia to accurately
identify how policy changes that affect out-of-pocket
healthcare costs will impact on the finances of patients
with cancer and their families, their decisions to access
care and clinical outcomes.
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